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Background: The E mutation in the AAA ATPase torsinA is associated with the neurological disease torsion dystonia.
Results: BiP and its co-factors maintain torsinA and torsinAE stability, glycosylation, and solubility.
Conclusion: torsinA/E, a chaperone-like protein, requires the assistance of other chaperones to fold.
Significance: Therapeutics that modulate BiP may counteract torsinAE-associated physiological defects.
Early-onset torsion dystonia (EOTD) is a neurological disor-
der characterized by involuntary and sustainedmuscle contrac-
tions that can lead to paralysis and abnormal posture. EOTD is
associated with the deletion of a glutamate (E) in torsinA, an
endoplasmic reticulum (ER) resident AAA ATPase. To date,
the effect of E on torsinA and the reason that this mutation
results in EOTD are unclear. Moreover, there are no specific
therapeutic options to treat EOTD. To define the underlying
biochemical defects associated with torsinAE and to uncover
factors that might be targeted to offset defects associated with
torsinAE, we developed a yeast torsinA expression system and
tested the roles of ER chaperones in mediating the folding and
stability of torsinA and torsinAE. We discovered that the ER
lumenalHsp70, BiP, an associatedHsp40, Scj1, and a nucleotide
exchange factor, Lhs1, stabilize torsinA and torsinAE. BiP also
maintained torsinA and torsinAE solubility. Mutations pre-
dicted to compromise specific torsinA functionalmotifs showed
a synthetic interaction with the E mutation and destabilized
torsinAE, suggesting that the E mutation predisposes
torsinA to defects in the presence of secondary insults. In this
case, BiP was required for torsinAE degradation, consistent
with data that specific chaperones exhibit either pro-degrada-
tive or pro-folding activities. Finally, using two independent
approaches, we established that BiP stabilizes torsinA and
torsinAE in mammalian cells. Together, these data define BiP
as the first identified torsinA chaperone, and treatments that
modulate BiP might improve symptoms associated with EOTD.
In order to function proteins need to acquire proper second-
ary and tertiary structures. Although the amino acid sequence
of a protein is a major determinant of its final fold, most pro-
teins acquire intermediate folding states during translation that
require the help of molecular chaperones and folding enzymes
(1–5). Chaperones not only maintain protein solubility and
facilitate folding but they also recognizemisfolded proteins and
target them for degradation via protein quality control path-
ways (6–11). Indeed, cell survival depends on the efficiency of
these pathways, as defects in pathway function are lethal when
cells are exposed to various stresses. Moreover, misfolded pro-
teins that are not cleared from the cell can severely impact cel-
lular physiology. These proteins can aggregate, they can gain a
dominant negative function, and/or they can deplete chaper-
ones, thereby exacerbating the accumulation of misfolded pro-
teins and compromising protein homeostasis or “proteostasis”
(12–15). Among all the proteins in the eukaryotic cell, approx-
imately one-third enter the secretory pathway through the
endoplasmic reticulum (ER)4 and either remain in the ER, are
secreted from the cell, or are ultimately distributed among the
plasma membrane, endosomes, vacuole/lysosomes, or Golgi
apparatus. In the secretory pathway, misfolded proteins are
cleared through diverse mechanisms, beginning with ER-asso-
ciated degradation (ERAD), which represents a critical step in
the protein quality control of secretory proteins (10, 11, 16).
A key chaperone that is required for protein folding in the ER
is the lumenal Hsp70, BiP/GRP78 (also known as Kar2 in Sac-
charomyces cerevisiae) (17–19). Kar2/BiP is also a major con-
tributor to general ER homeostasis, not only by participating in
protein folding and protein translocation, assembly, and quality
control, but also by regulating calcium homeostasis and ER
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stress signaling, including the unfolded protein response (20,
21). Kar2/BiP acts in conjunction with several co-factors that
regulate its ATP hydrolytic activity and therefore its ability to
bind substrates (21). These co-factors include theHsp40s Erdj3
and Erdj4 (Scj1 and Jem1 in yeast) and the nucleotide
exchange factors (NEFs) GRP170 and Sil1 (Lhs1 and Sil1 in
yeast) (16, 22–30). Perhaps not surprisingly, BiP has also been
associatedwith humandiseases, including cancer, diabetes, and
neurological disorders such as Parkinson disease and retinitis
pigmentosa. These attributes suggest that BiP is a therapeutic
target for the treatment of these ailments (31–33).
Many neurological disorders in humans are associated with
defects in protein folding, in the function of the secretory path-
way, or in protein quality control (34, 35), including amyo-
trophic lateral sclerosis, Parkinson,Huntington, andAlzheimer
diseases, and prion diseases (36–40). Dystonia, the third most
commonmovement disorder in humans, is also associatedwith
defects in these pathways (41). Dystonia manifests as involun-
tary muscle contractions that can lead to paralysis and abnor-
mal postures due to the simultaneous contraction of agonist
and antagonist muscles (41, 42). A common inherited primary
dystonia is early-onset generalized torsion dystonia (EOTD,
also known as childhood onset torsion dystonia). EOTD is asso-
ciated with an autosomal mutation in DYT1 (43, 44). Although
dominant, the mutation in DYT1 has low penetrance, indicat-
ing the existence of other environmental and genetic factors
that are critical for EOTDdevelopment (45). The average age of
EOTD onset is13 years, usually beginning in the lower limbs
and spreading to other parts of the body. Brain biopsies from
those afflicted with EOTD indicate the presence of inclusion
bodies and neuronal cell enlargement, without associated neu-
rodegeneration or neuronal cell death (46, 47). This lack of neu-
rodegeneration suggests that therapeutic treatment for this
chronic yet progressive movement disorder is possible (41).
DYT1 encodes torsinA, an ER- and nuclear envelope-local-
ized ATPase that belongs to the AAA ATPases superfamily.
AAA ATPases are a diverse group of enzymes that contain
characteristic ATP-binding and hydrolysis domains defined by
the Walker-A, Walker-B, Sensor-I, and Sensor-II motifs (Fig.
1A) (48). AAA ATPases can remodel protein complexes or
alter protein conformation, and many of them play important
roles in dissolving aggregates and in protein quality control,
including ClpA, FtsH, Hsp104, p97/Cdc48, and one subassem-
bly embedded within the 26 S proteasome (48–51). Indeed,
torsinA appears to function as a chaperone and participates in
ER protein quality control and the secretory pathway (48,
52–56). Until now it was unknown whether torsinA itself
required the assistance of chaperones to aid in its maturation.
Themost commonDYT1mutation associated with EOTD is
the deletion of a single glutamate residue from the Glu-302/
Glu-303 pair near theC terminus of torsinA (“torsinAE”) (Fig.
1A). Deletion ofGlu-302/Glu-303 causes a variety of alterations
in torsinA’s properties, including protein stability, degradation,
subcellular localization, conformational change, andmolecular
interactions (57–68). How these alterations lead to EOTD is
undetermined, which precludes the rational design of targeted
therapies to control EOTD progression or prevent the disease.
To identify chaperones that aid in torsinA folding and that
might be targeted to correct disease phenotypes associatedwith
theE allele, we co-opted the genetic tools available in the yeast
S. cerevisiae and designed a new torsinA and torsinAE expres-
sion system.Yeasts have beenused to define themolecular basis
underlying several human diseases, including amyotrophic lat-
eral sclerosis, antitrypsin deficiency, cancer, and Huntington,
Alzheimer, and Parkinson diseases, among many others (69–
72). Using this system, we found that Kar2/BiP and its Hsp40,
Scj1, as well as the Kar2/BiP-associated NEF, Lhs1, contribute
to torsinA and torsinAE stabilization in the ER.We also found
that Kar2/BiP plays a dual role in controlling torsinA stability,
depending on the presence of the E mutation and/or of sec-
ondary mutations in unique functional motifs. Furthermore,
Kar2/BiP affects torsinA and torsinAE solubility andN-linked
glycosylation, consistent with a role in mediating protein fold-
ing. Finally, by depleting BiP levels in a mammalian cell model,
we confirmed that BiP facilitates torsinA and torsinAE bio-
genesis. Together, these data represent the first demonstration
of the cellular chaperones that orchestrate torsinAmaturation.
EXPERIMENTAL PROCEDURES
Plasmid and Yeast Strain Construction—The pcDNA3.1-
torsinA and pcDNA3.1-torsinAE expression plasmids were
kindly provided by Dr. Xandra Breakefield (65). The torsinA
and torsinAE open reading frames (ORF)were subcloned into
the yeast expression vector pRS426GPD (73) by double restric-
tion enzyme digestion with EcoRI/XhoI (Fermentas, Thermo
Scientific) of pcDNA3.1-torsinA and pcDNA3.1-torsinAE
and ligation into EcoRI/XhoI-linearized pRS426GPD (Fig. 1B).
To construct HA-tagged torsinA and torsinAE vectors, a sin-
gle HA tag was introduced at the C terminus of torsinA and
torsinAE by in vivo recombination in S. cerevisiae following a
previously published protocol (74). Briefly, primers LZJB12 and
-13, encoding the HA tag sequence (Table 1), were annealed
and co-transformed into S. cerevisiae together with NotI-di-
gested pRS426GPD-torsinA or torsinAE. Recombined plas-
mids were extracted from S. cerevisiae and transformed into E.
coli DH5 for amplification.
Vectors containing the torsinA genes with mutations in
the N-linked glycosylation sites, pLuBr85 (torsinA-N143Q),
pLuBr86 (torsinAE-N143Q), pLuBr87 (torsinAE-N158Q),
pLuBr100 (torsinA-N158Q), and pLuBr106 (torsinA-N143Q,
N158Q) or at Asp-216, pLuBr60 (torsinA-D216H), and
pLuBr61 (torsinAE-D216H) (Fig. 1A and Table 2) were made
using the QuikChange Lightning site-directed mutagenesis kit
(Agilent Technologies) using primers LZJB21–24 or LZJB17–
18, respectively, thatwere designedusing theQuikChangePrimer
design application available online (Table 1). pRS426GPD-tor-
sinA, pRS426GPD-torsinAE, and pLuBr100were then used as
the template in a mutagenic PCR using primers LZJB21 and
LZJB22 to introduce the N143Q single mutation and LZJB23
and LZJB24 to introduce the N158Q single mutation. Muta-
tions in the Walker-A (K108A) and -B (E171Q) motifs in
torsinA and torsinAE were generated as above, with primer
pairs K108A-F and K108A-R and E171Q-F and E171Q-R
(Table 1), respectively. The mammalian expression vectors
pcDNA3.1-torsinA and pcDNA3.1-torsinAE were used as
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templates. These constructs were then subcloned into
pRS426GPD through EcoRI/XhoI digestion and ligation to
generate the yeast expression vectors containing a single muta-
tion in theWalker-Amotif (K108A; pLuBr20 and -23) orWalk-
er-B motif (E171Q; pLuBr21 and -24) (Fig. 1A and Table 2).
Similarly, the torsinA constructs lacking theN-terminal hydro-
phobic domain (Fig. 1A), torsinA-24–40 and torsinAE-
24–40, were subcloned by EcoRI/XhoI digestion and ligation
from pcDNA3.1-torsinA-24–40 and pcDNA3.1-torsinAE-
24–40 (75) into pRS426GPD, to generate pLuBr18 and
pLuBr19, respectively (Table 2). The sequence integrity of all
the subcloned DNA fragments and mutagenized sequences
was verified by DNA sequence analysis using primers CG_
GPDprom and LZJB5 which anneal at theGPD promoter and
CYC1 terminator regions in pRS426GPD, respectively
(Table 1 and Fig. 1B).
All S. cerevisiae strains used in this study are described in
Table 3. To construct the strains containing a deletion of the
PDR5 or PEP4 ORFs in the kar2-1 strain background, the
pdr5::KanMX and pep4::KanMX deletion cassettes contain-
ing200 bp of homology region upstream and downstream of
each ORF were PCR-amplified (Pfu Turbo, Agilent) fromDNA
extracted from the corresponding deletion mutant in the hap-
loid BY4742 S. cerevisiae deletion strain collection (Open Bio-
systems, Thermo Scientific) using primer pairs LZJB69 and -70
(for PDR5) and LZJB34 and -35 (for PEP4) (Table 1), and trans-
formation of these cassettes into the kar2-1 strain (Table 3).
The correct genotype of the mutants was confirmed by PCR
analysis of genomic DNA of strains resistant to the antibiotic
geneticin sulfate G418 (Research Products International Corp.)
using primer pairs LZJB71 and -72 (for PDR5) and LZJB44 and
-45 (for PEP4), as well as the KanB primer (CTGCAGCGAG-
GAGCCGTAAT), which anneals to theKanMX gene (Table 1).
The phenotypes of the constructed strains were verified as fol-
lows. Deletion of PEP4 was verified by a defect in the matura-
tion of the vacuolar protease aminopeptidase 1 (Ape1) (76), and
deletion of PDR5 was verified by a general increase in the level
of ubiquitinated proteins in MG132 (Peptide Institute Inc.,
Japan)-treated cells (data not shown) (77, 78). All yeast trans-
formations were performed using lithium acetate/PEG3350,
and DNA extractions were performed following standard pro-
tocols (79, 80).
Media and Growth Conditions—Yeast strains were grown at
26–28 °C on YPD medium (1% yeast extract, 2% peptone, 2%
dextrose) or on synthetic complete (SC) medium lacking
specific amino acids required for auxotrophic selection, as
described previously (81). For selection of KanMX-expressing
strains, YPD plates were supplemented with 250 g/ml G418.
TorsinA Secretion Assays—Overnight cultures of yeast cells
grown at 26–28 °C in selective medium were spotted onto a
nitrocellulosemembrane. Themembranewas layered on top of
solid selective medium, and plates were incubated 20 h at
30 °C. To detect secreted protein or total cell protein (which
includes the secreted material), we followed a previously pub-
lished protocol (82). The membranes were then probed for the
TABLE 1
Primers used in this study
Name Sequence 5 to 3 Ref.
LZJB5 CCTTCCTTTTCGGTTAGAGCGGA This study
LZJB12 ACGGTGTTCACCAAGTTAGATTATTACTACGATGATTACCCATACGATGTTCCAGATTACGCTTGAGCGGCCG
CTCGAGTCATGTAATTAGTTATGTCA
This study
LZJB13 TGACATAACTAATTACATGACTCGAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTAATCATCGTAG
TAATAATCTAACTTGGTGAACACCGT
This study
LZJB17 GAGCAGAAAGGATCACACATGTGGCTTTGGATTTC This study
LZJB18 GAAATCCAAAGCCACATGTGTGATCCTTTCTGCTC This study
LZJB21 TTGCACTTTCCACATGCTTCACAAATCACCTTGTACAAGGATCAG This study
LZJB22 CTGATCCTTGTACAAGGTGATTTGTGAAGCATGTGGAAAGTGCAA This study
LZJB23 GTTGTGGATTCGAGGCCAAGTGAGTGCCTGTGCGA This study
LZJB24 TCGCACAGGCACTCACTTGGCCTCGAATCCACAAC This study
LZJB34 AGTAAAGAAGTTTGGGTAATTCGCT This study
LZJB35 AGTGTTCTATGTTTGCCTTGATTTC This study
LZJB44 TCATTTGCGGGTGTCGATGG This study
LZJB45 CGTTGATGGCCTCCTTAAGC This study
LZJB69 TTGAACGTAATCTGAGCAATACAAA This study
LZJB70 TCACACTAAATGCTGATGCCTATAA This study
LZJB71 TCCTACTTATGGTAATGTGC This study
LZJB72 TAACTATATCCATTGCGTCC This study
CG_GPD prom CCCTGAAATTATTCCCCTACTTG This study
K108A-F GGACAGGCACCGGCGCAAATTTCGTCAGCAAG This study
K108A-R CTTGCTGACGAAATTTGCGCCGGTGCCTGTCC This study
E171Q-F CCATCTTCATATTTGATCAAATGGATAAGATGCATGC This study
E171Q-R GCATGCATCTTATCCATTTGATCAAATATGAAGATGG This study
TABLE 2
Plasmids used in this study
Details Plasmid no. Ref.
pcDNA3.1-torsinA 65
pcDNA3.1-torsinAE 65
pcDNA3.1-torsinA-HA 63
pcDNA3.1-torsinAE-HA 63
pRS426GPD-torsinA pLuBr281 This study
pRS426GPD-torsinAE pLuBr280 This study
pRS426GPD-torsinA-HA pLuBr27 This study
pRS426GPD-torsinAE-HA pLuBr28 This study
pRS426GPD-torsinA-N143Q pLuBr85 This study
pRS426GPD-torsinA-N158Q pLuBr100 This study
pRS426GPD-torsinAE-N143Q pLuBr86 This study
pRS426GPD-torsinAE-N158Q pLuBr87 This study
pRS426GPD-torsinA-N143,N158Q pLuBr106 This study
pRS426GPD-torsinA-D216H pLuBr60 This study
pRS426GPD-torsinAE-D216H pLuBr61 This study
pRS426GPD-torsinA-K108A pLuBr20 This study
pRS426GPD-torsinA-E171Q pLuBr21 This study
pRS426GPD-torsinAE-K108A pLuBr23 This study
pRS426GPD-torsinAE-E171Q pLuBr24 This study
pRS426GPD-torsinA-24–40 pLuBr18 This study
pRS426GPD-torsinAE-24–40 pLuBr19 This study
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presence of torsinA or G6PDH and developed as described
below.
Biochemical Methods—To assess protein stability, cells were
grown overnight in selective medium at 28 °C, diluted to an
initial A600 of 0.2 in fresh medium, and incubated at the same
temperature for6 h to an A600 of1. Cycloheximide (CHX)
(Sigma) was added to a final concentration of190 g/ml, and
cells were incubated at 37 °C for 90 min. A 1-ml aliquot was
taken before adding CHX (time 0 min) and every 30 min after
adding CHX. The cells were then pelleted by centrifugation at
18,000  g for 1 min at 4 °C. The cell pellet was immediately
frozen in liquid nitrogen. Samples were processed for Western
blot analysis as described below. To inhibit the proteasome,
cells were preincubated in the presence ofMG132 for 30min at
37 °C before addition of CHX.
Yeast protein extracts were prepared as described previously
(83). Samples were resuspended in 50 l of trichloroacetic acid
(TCA) sample buffer (80 mM Tris, pH 8, 8 mM EDTA, pH 8,
3.5% SDS, 5% glycerol, 0.4% Tris base, 0.01% bromphenol blue,
and 4% fresh 2-mercaptoethanol), disrupted for 20 s with a
mechanical pestle, heated at 75 °C for 5 min, resolved by SDS-
PAGE, and fast-transferred to nitrocellulose membranes (fast
semi-dry blotter, Thermo Scientific Pierce).
Protein extractions from mammalian cells were performed
as follows. Cells were washed with cold PBS, resuspended in
RIPA buffer with protease inhibitors (Roche Applied Science),
rocked at 4 °C for 40 min, and harvested. The cell suspension
was then centrifuged at 18,000  g for 10 min at 4 °C, and the
supernatant was used for Western blotting.
The following antibodies were used for Western blot analy-
sis: rabbit polyclonal anti-torsinA, produced by Cocalico Bio-
logicals (Reamstown, PA), that was made against a soluble
lumenal domain of human torsinA (residues 41–332), which
was expressed in Drosophila S2 cells and purified (75); mouse
monoclonal anti-torsinAD-M2A8 (Cell Signaling); rabbit poly-
clonal anti-G6PDH (Sigma); rabbit polyclonal anti-Kar2 (84);
rabbit polyclonal anti-Pdi1 (a gift from V. Denic, Harvard Uni-
versity, Cambridge, MA); rabbit polyclonal anti-Sec61 (85);
rabbit polyclonal anti-Bos1 (a gift from C. Barlowe, Geisel
School of Medicine at Dartmouth University, Hanover, NH);
mouse monoclonal horseradish peroxidase (HRP)-conjugated
anti-HA (clone 3F10, Roche Applied Science); goat polyclonal
anti-GRP78 (C20, SantaCruz Biotechnology);mousemonoclo-
nal anti- actin ab6276 (Abcam); rat monoclonal anti-Grp94
(9G10, Enzo Life Sciences); and sheep or goat HRP-conjugated
anti-mouse, anti-rat, anti-goat, or anti-rabbit IgG secondary
antibodies (GE Healthcare and Cell Signaling). Western blots
were developed with Supersignal West Pico or Supersignal
West Femto Chemiluminescent Substrate (Pierce), and
images were visualized using a Kodak 440CF Image Station.
The signal was quantified using ImageJ Version 1.46r
(National Institutes of Health).
To monitor the acquisition of N-linked glycosylation, whole
cell protein extracts were digested with 50 milliunits of
endoglycosidase H (Roche Applied Science) for 1 h at 37 °C in
the presence of 1 mM PMSF and 100 mM KOAc. Samples were
resolved by SDS-PAGE and used for Western blotting, as
described above.
To measure protein extraction from microsomal membranes,
ER-derived microsomes were prepared from cells grown over-
night in selectivemedium at 28 °C, diluted to anA600 of 0.2, and
incubated at the same temperature for6 h to anA600 of1.2.
A total of 60 absorbance units of cells were harvested and fro-
zen. The pellets were thawed on ice and resuspended in 600 l
of lysis buffer (20mMHepes, pH7.4, 50mMKOAc, 2mMEDTA,
pH 8, 100 mM sorbitol, 1 mM dithiothreitol (DTT)). A total of
500 l of glass beads were added, and samples were agitated
on a Vortex mixer seven times for 60 s, with a 60-s incubation
on ice between each treatment. The lysate was collected in an
Eppendorf tube and centrifuged twice at 3000 rpm in a tabletop
centrifuge at 4 °C for 5 min to remove cell debris and unbroken
cells. The supernatant was then centrifuged at 18,000  g at
4 °C for 20 min to collect the microsomes, which were washed
in 500l of Buffer 88 (20mMHepes, pH 6.8, 150mMKOAc, 250
mM sorbitol, 5 mM MgOAc) and centrifuged as above. Mem-
branes were resuspended in Buffer 88, and the protein concen-
tration was adjusted spectrophotometrically by measuring the
A280 in 2% SDS. Next, 20 l of the isolated microsomes were
resuspended in 1 ml of the following buffers: Buffer 88, pH 6.8,
1% Triton X-100 (Sigma) in Buffer 88, pH 6.8, 0.1 M freshly
prepared sodium carbonate in water, 25 mM CHES buffer, pH
9.5, 25 mM CAPS buffer, pH 10.5, or 6 M urea in 37.5 mM Tris,
pH 8, 2mMEDTA.After the samples were incubated for 30min
on ice, the samples were centrifuged at 100,000  g for 1 h at
4 °C in a Sorvall RC M120EX ultracentrifuge. The pellets were
washed with 500 l of Buffer 88, and re-centrifuged at
TABLE 3
Strains used in this study
Strain Genotype Reference
BY4742 MAT his31 leu20 lys20 ura30 Open Biosystems
lhs1 MAT his31 leu20 lys20 ura30 lhs1::KanMX Open Biosystems
KAR2 MATa leu2-3,112 ura3-52 ade2-101 103
kar2-1 MATa leu2-3,112 ura3-52 ade2-101 kar2-1 103
kar2-1 pep4 MATa leu2-3,112 ura3-52 ade2-101 kar2-1 pep4::KanMX This study
kar2-1 pdr5 MATa leu2-3,112 ura3-52 ade2-101 kar2-1 pdr5::KanMX This study
JEM1 SCJ1 MAT prc1-1 leu2-3,112 ura3-52 trp1-901 his3-200 lys2-801 suc2-9 GAL 29
jem1 MAT prc1-1 leu2-3,112 ura3-52 trp1-901 his3-200 lys2-801 suc2-9 GAL jem1::LEU2 29
scj1 MAT prc1-1 leu2-3,112 ura3-52 trp1-901 his3-200 lys2-801 suc2-9 GAL scj1::TRP1 29
jem1 scj1 MAT prc1-1 leu2-3,112 ura3-52 trp1-901 his3-200 lys2-801 suc2-9 GAL jem1::LEU2 scj1::TRP1 29
CNE1 MATa leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 can1-100 145
cne1 MATa leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 can1-100 cne1::LEU2 145
CNE1 MAT leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 can1-100 145
cne1 MAT leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 can1-100 cne1::LEU2 145
yos9 MAT his31 leu20 lys20 ura30 yos9::KanMX Open Biosystems
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146,000  g for 15 min at 4 °C. The supernatants were trans-
ferred to Eppendorf tubes, and total proteinwas precipitated by
adding 110 l of 100% TCA and incubating on ice for 15 min,
followed by a centrifugation at 18,000  g for 10 min at 4 °C.
Pellets from samples containing Triton X-100 were washed
with acetone. All pellets were resuspended in 35 l of TCA
sample buffer, and proteins were resolved by SDS-PAGE and
examined by Western blotting. All buffers were supplemented
with a proteinase inhibitor mixture.
For protease protection assays, protease inhibitors were
removed from themicrosomes bywashing them twice with 500
l of Buffer 88. The washed microsomes were incubated on ice
for 30 min in the presence or absence of 1% Triton X-100,
followed by a 1-h incubation on ice in the presence or absence
of 50 g/ml proteinase K (Sigma). Proteins were precipitated
with 500 l of ice-cold 10% TCA and centrifuged at 18,000 g
for 10 min at 4 °C. Pellets were resuspended in 30 l of TCA
sample buffer. Samples were resolved by SDS-PAGE and ana-
lyzed by Western blotting.
For protein co-immunoprecipitation studies, yeast cells were
grown overnight in selective medium at 28 °C, diluted to an
A600 of 0.2, and grown at the same temperature for6 h to an
A600 of 1.2. A total of 45 absorbance units of cells were
harvested and frozen. The pellets were thawed on ice and resus-
pended in 600l of lysis buffer supplemented with 0.5% Triton
X-100 and a protease inhibitormixture and transferred to boro-
silicate tubes containing500 l of glass beads. Samples were
agitated on a Vortex mixer 9 times for 60 s, with 60 s of
incubation on ice between each treatment. The lysate was col-
lected in an Eppendorf tube and centrifuged twice at 3000 rpm
in a tabletop centrifuge at 4 °C for 5 min to remove cell debris
and unbroken cells. The supernatant was further cleared by
centrifuging twice at 18,000 g at 4 °C for 20 min. The protein
concentration was adjusted spectrophotometrically by mea-
suring the A280 of an aliquot in 2% SDS. Extracts were pre-
cleared by incubation for 1.5 h at room temperature with 30 l
of protein G-agarose (Roche Applied Science) and then incu-
bated overnight with 30 l of protein G-agarose (Roche
Applied Science) in the presence or absence of 1l of anti-Kar2
antiserum. Beads were washed four times with 500 l of wash
buffer (20 mM Hepes, pH 7.4 (buffered with KOH), 150 mM
NaCl, and supplemented with a protease inhibitor mixture). 30
l of TCA sample buffer was added to the beads, and proteins
were extracted by heating the beads for 5–7 min at 75 °C. Sam-
pleswere resolved by SDS-PAGEand analyzed byWestern blot.
Indirect Immunofluorescence Microscopy—The preparation
of yeast for indirect immunofluorescence was performed fol-
lowing a previously published protocol (86). Briefly, cells were
grown overnight in selective medium at 28 °C, diluted to an
A600 of 0.3 in fresh medium, and grown at 28 °C for5 h to an
A600 of 0.7. To fix the yeast, 37% formaldehyde was added
(final concentration of 4%), and the cells were incubated for 10
min at 28 °Cwith shaking. The cell suspension was centrifuged,
and the pelleted yeast were resuspended in 5ml of KM solution
(40 mM KPO4, pH 6.5, 0.5 mM MgCl2) with 4% formaldehyde
and incubated for 1 h at 28 °C with shaking. The cells were
washed twice with KM solution and once with KM solution
supplemented with 1.2 M sorbitol (KM  sorbitol) and were
resuspended in 500 l of KM  sorbitol. Next, the cell walls
were digested with 30 l of 10 mg/ml Zymolyase (20T, MP
Biomedicals LLC) for no more than 25 min at 37 °C, and the
spheroplasts were washed with KM  sorbitol buffer, resus-
pended in 500l of the same buffer, and incubated overnight at
4 °C. A 20-l aliquot of the cell suspensionwas spotted on poly-
lysine-coated slides, and the cells were dehydrated with meth-
anol/acetone, blocked with PBS, pH 7.4, supplemented with
0.5% BSA, 0.5% ovalbumin, and 0.1% Triton X-100, and incu-
bated at 37 °C for 1 h. Primary antibodies (mouse anti-HA
12CA5 (Roche Applied Science) (1:100) or rabbit anti-Kar2
(1:250)) diluted in blocking solution were applied, and the cells
were incubated overnight at 4 °C, before secondary antibodies
(Alexa Fluor 488 anti-mouse and Alexa Fluor 569 anti-rabbit
(1:250)) were added for 1 h at room temperature. The slides
weremounted using Prolong Gold Antifade reagent with DAPI
(Invitrogen). Pictures were taken using a Leica TCS SP5 confo-
cal microscope, 63 oil immersion objective, and analyzed
with Adobe Photoshop (Version 7.0) software.
Analysis of TorsinA and TorsinAE Stability and Biogenesis
in HeLa Cells—HeLa Tet-On cells (Clontech) were maintained
in DMEM (Invitrogen) supplemented with antibiotics and 10%
fetal bovine serum at 37 °C in a 5% CO2 humidified incubator.
Vectors engineered for the transient expression of torsinA/E
or C-terminal HA-tagged versions of torsinA/E (Table 2)
were transfected using Lipofectamine 2000 (Invitrogen) follow-
ing the manufacturer’s instructions (the medium was changed
3.5–4 h post-transfection). siRNA transfections were per-
formedusingRNAiMax (Invitrogen) (themediumwas changed
7 h post-transfection). In these experiments, the torsinA
expression vectors were transfected into siRNA-treated cells
24 h after the siRNAs had been introduced. The following
Stealth siRNAs (Invitrogen) were used: HSS105077 and
HSS179390 against BiP/GRP78, and Stealth RNAi siRNA Neg-
ative Control Medium GC (Invitrogen), at a concentration of
1.6 nM. Protein extracts were prepared from cells incubated for
another 24 h (a total of 48 h after siRNA transfection). Although
higher efficiency of BiP knockdown can be achieved, our pro-
tocol was adjusted to minimize cell toxicity (2). As an alterna-
tive means to deplete the levels of BiP, we employed the AB5
subtilase cytotoxin (87).
To monitor torsinA stability, pulse chase analyses were per-
formed as previously published (63) and included a 30-min
starvation period and a 15-min labeling period with 200 Ci/
well of [35S]Met/Cys (ICN Biochemicals) in a 6-well plate. Pro-
tein levels at the indicated time points were analyzed after
immunoprecipitation with mouse monoclonal anti-HA 16B12
(Covance) and protein G-agarose (Roche Applied Science)
using aTyphoonFLA7000 and associated software (version 1.2)
(General Electric). Where indicated, the active subtilase toxin
or an inactive mutant (SubAA272B) was added to a final con-
centration of 0.5 g/ml during amino acid starvation and was
present throughout the labeling and chase steps.
Statistical Analysis—Statistical analyses were performed
using Student’s t test (Microsoft Excel Software), assuming
equal variances. A p value 0.05was considered significant. All
statistical analyses of protein degradation assays were per-
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formed only with the values at the end of the chase, because
they reflect maximal differences between data sets.
RESULTS
A Yeast Model to Study TorsinA and TorsinAE Biogenesis—
To express torsinA and torsinAE in S. cerevisiae, we sub-
cloned the ORF of torsinA and torsinAE into the multicopy
yeast expression vector pRS426 (73), placing torsinA under the
control of the constitutive glyceraldehyde-3-phosphate dehy-
drogenase promoter (Fig. 1B). In this system, torsinA and
torsinAE were expressed at similar levels and migrated by
SDS-PAGE as an 33-kDa species, which corresponds to the
monomeric forms of the proteins (Fig. 1C). Endoglycosidase H
treatment of torsinA and torsinAE protein extracts produced
a faster migrating band, indicating that both torsinA and
torsinAEwereN-glycosylated in yeast, as shown previously in
mammalian cells (Fig. 1C) (65). Also, in accordancewith results
in mammalian cells, torsinA-HA and torsinAE-HA were
localized in the ER/nuclear envelope compartments, as evi-
denced by co-localization with the ER chaperone, Kar2/BiP
(Fig. 1D). Similar results were obtained using sucrose density
gradients with untagged torsinA and torsinAE and through
live cell fluorescence imaging of GFP-tagged forms of torsinA
and torsinAE (data not shown).
TorsinA is a monotopic membrane protein (88) and behaves
like a peripherally associated protein in mammalian cells (89).
To determine whether this was also the case in yeast, we per-
formed alkaline extractions using isolated ER-derived micro-
somalmembranes from yeast expressing torsinA or torsinAE,
following a previously published method for torsinA (89). All
proteins remained associated with the microsomal pellet frac-
tion at pH 6.8, as expected (Fig. 2A, lanes 1 and 2 and 9 and 10).
At pH 9.5, both Pdi1, a soluble lumenal protein, and Kar2/BiP,
a peripherally associated protein (90), were partially released
into the supernatant. However, at pH 9.5, torsinA and
torsinAE remained associated with the pellet (Fig. 2A, com-
pare lanes 3 and 4 and 11 and 12). At pH 10.5, Pdi1 was almost
completely released into the supernatant, whereas a consider-
able fraction of torsinA and torsinAE remained associated
with the pellet fraction, similar to Kar2/BiP (Fig. 2A, compare
lanes 5 and 6 and 13 and 14). At pH11.5, Pdi1 was completely
solubilized, while both torsinA and torsinAE were largely
extracted, similar to Kar2/BiP (Figs. 2A, compare lanes 7 and 8
and 15 and 16, and 7C). The transmembrane protein Sec61
FIGURE1.TorsinAand torsinAEareER-localizedN-glycosylatedproteins in yeast.A, SS, signal sequence;C, cysteines;N143 andN158,N-glycosylatedAsn
residuesmutated in Fig. 8;K108 and E171, residuesmutated in Fig. 8 that belong to theWalkermotifs;D216,mutation that impactsEpenetrance; E302or E303,
glutamate residue deleted in patients with EOTD. Walker-A and -B, and Sensor-I and -II motifs (for ATP binding and hydrolysis) are indicated by black lines. B,
ORFsof torsinAand torsinAEwere cloned into themulticopy shuttle vectorpRS426andareunder the control of the constitutiveglyceraldehyde-3-phosphate
dehydrogenase (GPD) promoter. C, protein samples were prepared from log phase wild-type yeast cells transformed with empty vector (V) or expression
vectors for torsinA (T) or torsinAE (E) grownat 28 °C andwere treatedwith endoglycosidaseH (EndoH) as indicated. Theglycosylated speciesmigrate at33
kDa and the unglycosylated species resolve at 27 kDa. The * indicates a background band of the antibody. D, indirect immunofluorescence of log phase
wild-typeyeast cells transformedwithexpressionvectors for torsinA-HAor torsinAE-HAor anemptyvector control grownat 28 °C. TheER lumenal chaperone
Kar2/BiP and the nuclear concentrated dye DAPI were used as controls.
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remained associated with the pellet at each pH, as expected.
Treatment with 6 M urea efficiently released Pdi1, Kar2/BiP,
and both torsinA variants but not Sec61, as expected (Fig. 2A,
lanes 17–20). Overall, torsinA and torsinAE behaved more
similarly to Kar2/BiP than to Pdi1, indicating that torsinA and
torsinAE are peripherally membrane-associated proteins in
yeast.
An N-terminal hydrophobic domain (HD; Fig. 1A) anchors
torsinA to the lumenal side of the ERmembrane (75, 89, 91). To
test whether the HD was responsible for maintaining torsinA
in the yeast ER, as anticipated, we examined whether torsinA,
torsinAE, and versions lacking the HD (torsinA-24–40 and
torsinAE-24–40) were secreted from cells by using a dot
blot technique (82, 92). Cells expressing each torsinA variant or
harboring an empty vector control were spotted onto nitrocel-
lulose membranes. After 20 h of incubation on medium, we
either lysed the cells in situ (to assess total protein) or removed
the cells with vigorous washing (to examine secreted protein,
which adhered to the membrane). We then performed an
immunoblot for torsinA and the nonsecreted cytosolic protein
G6PDH (Fig. 2B). As expected, we observed that torsinA-
24–40 and torsinAE-24–40 were secreted, while torsinA,
torsinAE, and G6PDH were not. Therefore, similar to mam-
malian cells, the N-terminal HD of torsinA prevents torsinA
secretion to the extracellularmedium, suggesting that this domain
is properly folded and helps maintain torsinA and torsinAE in
the yeast ER (75, 88).
Together, these data indicate that torsinA and torsinAE are
N-linked glycosylated ER resident proteins that are peripherally
associated with the ER membrane in yeast, as in mammalian
cells. Because these basic cellular properties of torsinA are con-
served in yeast, we pursued subsequent studies to define how
torsinA and torsinAE impact cellular homeostasis and which
cellular factors regulate their protein stability.
TorsinA can modulate the ER stress response, and torsinA
overexpression leads to defects in ERAD and protein secretion
(53, 56, 93–95). To test whether torsinA or torsinAE expres-
sion in yeast induces a stress response or leads to any overt
phenotype, we compared the behavior of cells expressing
torsinA, torsinAE, or harboring an empty vector control. Cells
expressing torsinA or torsinAE showed no growth defect in
the absence or presence of several ER stressors (including heat
shock, tunicamycin, and DTT) compared with a strain trans-
formedwith an empty vector control (data not shown). Expres-
sion of torsinA or torsinAE in yeast also did not alter the heat
shock response of wild-type cells incubated at 39 °C nor did it
alter the unfolded protein response in wild-type cells incubated
in the presence of tunicamycin (data not shown). These data are
in-line with a recently published study in which the phenotypes
of yeast expressing torsinA were analyzed (96). In addition, the
degradation of the ERAD substrates CPY* and CFTR was unal-
tered by the co-expression of torsinA or torsinAE. Finally, no
morphological changes were evident in the nuclear envelope of
strains expressing torsinA or torsinAE, as determined by elec-
tronmicroscopy (data not shown) (53, 97, 98). These combined
data indicate that torsinA is not toxic when expressed in yeast.
Stability of TorsinAandTorsinAEDepends on the ERChap-
erone Kar2/BiP—Most of the current knowledge on torsinA is
concentrated on the function and biochemical properties of
torsinA and on the effect the E mutation has on these prop-
erties (59, 99). However, nothing is known about whether
molecular chaperones facilitate the folding, stabilization,
and/or degradation of torsinA and torsinAE. Using yeast as a
model system, we set out to identify which chaperones impact
torsinA and/or torsinAE biogenesis.
A critical ER resident chaperone that plays a role in both
protein folding and degradation is Kar2/BiP (17–19, 100–102).
To test the role of Kar2/BiP on torsinA and torsinAE stability,
we performed CHX chase experiments in a wild-type (KAR2)
strain and in a Kar2/BiP mutant (kar2-1) strain. The kar2-1
allele carries a temperature-sensitive mutation that compro-
mises ERAD and protein folding due to a defect in the con-
trolled release of bound peptide substrates (101, 103–105). We
first noted that there was no significant difference in the degra-
dation of torsinA and torsinAE in wild-type cells (Fig. 3A).
These results are in accordance with experiments in mamma-
lian cells showing identical torsinA and torsinAE turnover
when measured during a short time course (63). However, in
the kar2-1 strain both torsinA and torsinAEwere significantly
destabilized (55% versus 81% for torsinA and 59% versus 84%
for torsinAE remained after 90min in themutant strain versus
the wild-type strain, respectively) (Fig. 3A). The data suggest
that Kar2/BiP helps maintain the stability of torsinA and
torsinAE in yeast.
We noticed that torsinA and torsinAE expressed in the
kar2-1 strain migrated as three distinct bands, with the highest
molecular weight species migrating at the position of torsinA
FIGURE2.TorsinAand torsinAEperipherally associatewith theyeast ER
membrane through an N-terminal hydrophobic domain. A, ER-derived
microsomes were prepared from log phase wild-type yeast cells grown at
28 °C that expressed torsinA or torsinAE and were incubated in a pH 6.8
buffer, in 25 mM CHES, pH 9.5 buffer, 25 mM CAPS, pH 10.5 buffer, 0.1 M
Na2CO3, pH 11.5, or in 6 M urea for 30 min in ice. After centrifugation at
100,000 g, aliquots from the supernatant (S) or the pellet (P) fractions were
analyzed by SDS-PAGE, and the presence of torsinA and torsinAE was
detected by Western blot. Pdi1 is a lumenal ER protein; Kar2 is a peripherally
associatedER lumenal protein, andSec61 is an integralmembraneERprotein.
B, nitrocellulose membranes spotted with overnight yeast cultures trans-
formedwith vector alone (V) or expressing torsinA (T) or torsinAE (E), were
layered on top of solid selectivemediumand incubated for20 h at 30 °C. To
detect secreted proteins, cells were washed off the nitrocellulosemembrane
with water. To detect total protein (intracellular and secreted material), cells
were lysed in situ and then washed. TorsinA and G6PDH were detected by
Western (“dot”) blot. Please note that secreted proteins yield a higher signal
than their nonsecreted counterparts in the total protein blot (82).
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expressed in the wild-type strain (Fig. 3, B and C). Because
torsinA can beN-glycosylated at two asparagines, Asn-143 and
Asn-158 (Fig. 1A, and see below) (65, 106), we hypothesized
that the faster migrating bands corresponded to mono- and
unglycosylated torsinA. Indeed, the mobility of the middle
band coincided with the mobility of the torsinA-N143Q
mutant, which can only beN-monoglycosylated at the Asn-158
residue (30 kDa) (Fig. 3B). Similar results were obtained for
torsinAE (data not shown). This result indicates that, similar
to mammalian cells, torsinA and torsinAE areN-glycosylated
at both asparagines. Furthermore, the migration of the lowest
molecular weight species coincided with the mobility of
endoglycosidaseH-treated samples of torsinA and torsinAE
expressed in both the KAR2 and kar2-1 strains and with the
mobility of a torsinA-N143Q,N158Q double mutant (27
kDa) (Fig. 3B). Therefore, a loss of Kar2/BiP function leads to
inefficient N-linked glycosylation of torsinA and torsinAE.
Importantly, the effect of the kar2-1 mutation on torsinA is
specific because the N-linked glycosylation of other sub-
strates, such as CPY*, is unaffected by this mutation (data
not shown) (107).
Although the kar2-1 allele does not appear to impact protein
translocation into the ER (101), it was formally possible that the
mono- and unglycosylated torsinA species in the kar2-1 strain
arise from defective translocation. To exclude this possibility,
we performed a protease protection assay in the KAR2 and
kar2-1 strains expressing torsinA and torsinAE. If indeed the
mono- and unglycosylated torsinA species in the kar2-1 strain
were caused by a translocation defect, they would be exposed on
the surface of the microsomes and would be protease-accessible
even in theabsenceofdetergent.However, eachof the torsinAand
torsinAE species was stable after protease treatment (Fig. 3C,
compare lanes 1 and 2 and 4 and 5, 7 and 8, and 10 and 11). In
contrast, addition of 1% Triton X-100 initiated torsinA and
torsinAE degradation (Fig. 3C, compare lanes 2 and 3, 5 and 6, 8
and 9, and 11 and 12). Kar2/BiP was also protected from protease
in the absence of detergent but was clipped andmigrated faster in
the presence of detergent. The ER transmembrane protein Bos1,
which exposes an epitope to the cytosol (108), was proteolyzed in
the presence and absence of Triton X-100, as anticipated. These
results indicate that the differentially N-glycosylated torsinA and
torsinAE species are ER-encapsulated and support a role for
Kar2/BiP in torsinA and torsinAE N-linked glycosylation and
stability. Because a loss of protein stability is associated with mis-
folding (109), our data strongly suggest that Kar2/BiP functions as
a torsinA chaperone.
FIGURE 3. TorsinA and torsinAE stability in yeast depends on the ER chaperoneKar2/BiP.A, log phase yeast cells expressing torsinA or torsinAE grown
at 28 °Cwere treatedwith cycloheximide and then incubated at 37 °C for 90min. Samples were taken every 30min, and the amount of torsinA or torsinAE in
each time point was quantified relative to that at the 0-min time point. Data represent the average S.E. of at least four experiments with2 independent
replicates/experiment. The % of torsinA or torsinAE remaining after CHX addition in wild-type KAR2 or kar2-1 yeast strains is graphed (*, p 0.04 for KAR2
torsinA versus kar2-1 torsinA;p 0.003 forKAR2 torsinAE versus kar2-1 torsinAE). RepresentativeWesternblots are shown.B, torsinA and torsinAEN-linked
glycosylation is Kar2-dependent. Protein samples were prepared from log phase KAR2 and kar2-1 yeast strains as before, except that they were treated with
endoglycosidase H (EndoH) as indicated beforeWestern blot analysis. Pdi1 is anN-glycosylated protein, whereas G6PDH is a cytosolic unglycosylated protein.
* indicates a background band in the blot. C, torsinA and torsinAE glycosylated species are ER-embedded. Microsomes from KAR2 and kar2-1 strains
expressing torsinA and torsinAE were incubated on ice for 30 min in the presence or absence of Triton X-100, followed by a 1-h incubation on ice in the
presence or absence of proteinase K. Proteins were TCA-precipitated, resolved by SDS-PAGE, and analyzed by Western blot. Note that the ER protein Kar2 is
clipped by proteinase K in the presence of Triton X-100. Bos1 is an ER transmembrane protein with an epitope exposed to the cytosol that is proteinase
K-sensitive even in the absence of Triton X-100. UC, uncleaved Kar2/BiP; C, cleaved Kar2/BiP. D, Kar2/BiP co-immunoprecipitates with torsinA and torsinAE.
Whole cell extracts from KAR2 cells transformed with a vector control (V) or expression vectors for torsinA (T) or torsinAE (E) were immunoprecipitated (IP)
under native conditions (0.5%TritonX-100) using anti-Kar2 antiserum. Immunoprecipitatedmaterialwas resolvedby SDS-PAGEandanalyzedbyWesternblot.
Controls from immunoprecipitations in which primary antiserum was absent (	) were also included.
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If, as expected, Kar2/BiP is a torsinA chaperone, then both
proteins should physically interact. To test this hypothesis, we
obtained whole cell extracts from wild-type cells, immunopre-
cipitated Kar2/BiP under native conditions, and probed for
torsinA and torsinAE by Western blot. Both torsinA and
torsinAE co-precipitated with Kar2/BiP in the absence of
cross-linking agents (Fig. 3D). Only a relatively small fraction of
torsinA and torsinAE co-precipitatedwith Kar2/BiP, suggest-
ing a transient interaction. ProlongedHsp70-substrate interac-
tions normally lead to substrate degradation (110, 111). How-
ever, transient interactions between chaperones and their
substrates occur during substrate folding, as observed previ-
ously for Kar2/BiP (102, 112, 113). The combined data indicate
that Kar2/BiP is a pro-folding chaperone for torsinA and
torsinAE.
The ER Lumenal Hsp40 Scj1 and the Nucleotide Exchange
Factor Lhs1 Also Maintain TorsinA and TorsinAE Stability—
Kar2/BiP function in yeast is augmented by the action of co-
chaperones, including the Hsp40s Jem1 and Scj1 and the NEFs
Lhs1 and Sil1 (21, 114). Therefore, we compared torsinA and
torsinAE stability by CHX chase analysis in a jem1 scj1
strain to the wild-type strain (JEM1 SCJ1) (Fig. 4A). Similar to
the results observed in the kar2-1 strain (Fig. 3A), torsinA and
torsinAE stability was significantly decreased in the jem1
scj1 strain compared with the wild-type strain (55% versus
84% torsinA, and 62% versus 80% torsinAE remained after 90
min in themutant and wild-type strains, respectively) (Fig. 4A).
To determine whether one of the two Hsp40s played a more
important role in stabilizing torsinA and torsinAE, we per-
formed chase analyses in the jem1 and scj1 single mutant
strains. In agreement with previous reports showing a more
prominent role of Scj1 than Jem1 during protein maturation (27,
29), torsinA and torsinAE stability was exclusively SCJ1-depen-
dent (89% versus 48% torsinA and 83% versus 46% torsinAE
remainedafter 90min in the jem1 and scj1 strains, respectively)
(Fig. 4B). Interestingly, we observed a glycosylation defect in the
jem1 scj1mutant but not in the jem1 or scj1 single mutants
(Fig. 4, A and B). Therefore, although only Scj1 is required to sta-
bilize torsinA and torsinAE, both Hsp40s support efficient
torsinA and torsinAE glycosylation. These experiments suggest
that torsinA instability is independent of the glycosylation defect
caused by the absence of these chaperones.
To test the role of the NEFs on torsinA and torsinAE sta-
bility, we performed CHX chases in the lhs1 and sil1 strains
(Fig. 4C and data not shown). In accordancewith a recent paper
indicating a more prominent role for Lhs1 than Sil1 on ER pro-
tein biogenesis (115), the stability of torsinA and torsinAEwas
significantly decreased in the lhs1 strain compared with the
wild-type strain (70% versus 91% torsinA and 73% versus 92%
torsinAE remained after 90min in the lhs1 and thewild-type
strains, respectively) (Fig. 4C), whereas the sil1mutation had
no effect on torsinA or torsinAE stability (data not shown). In
the absence of Lhs1, there was no effect on glycosylation (Fig.
4C and data not shown), which is consistent with the proposal,
FIGURE4.TheER lumenalHsp40Scj1and thenucleotideexchange factorLhs1stabilize torsinAandtorsinAE.CHXchaseswereperformedasdescribed
before (see legend for Fig. 3). A, torsinA and torsinAE degradation in JEM1 SCJ1 and jem1 scj1 strains (*, p 0.002 for JEM1 SCJ1 torsinA versus jem1 scj1
torsinA; p 0.03 for JEM1 SCJ1 torsinAE versus jem1 scj1 torsinAE). B, torsinA and torsinAE degradation in jem1 and scj1 strains (*, p 0.0005 for
jem1 torsinA versus scj1 torsinA; p 0.02 for jem1 torsinAE versus scj1 torsinAE).C, torsinA and torsinAE degradation in LHS1 and lhs1 strains (*, p
0.04 for LHS1 torsinA versus lhs1 torsinA; p 0.02 for LHS1 torsinAE versus lhs1 torsinAE). Representative Western blots are shown below. Experiments
were performed at least twice, with2 independent replicates per experiment.
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above, that the defect in glycosylation is uncoupled from
torsinA stabilization. Together, these data strongly suggest that
Kar2/BiP functionswith a cognateHsp40, Scj1, aswell as aNEF,
Lhs1, to facilitate the folding of torsinA and torsinAE in
the ER.
Importantly, deletion of other ER chaperones had no impact
on the stability or N-linked glycosylation of torsinA and
torsinAE, indicating that these phenomena are not the result
of a general ER stress response (Fig. 5 and data not shown). For
example, deletion of the chaperone-like lectins Cne1 and Yos9
had no effect on these properties (Fig. 5). Preliminary data sug-
gest that Mnl1 (the yeast EDEM1 homolog (116)) also had no
effect on torsinA or torsinAE stability or glycosylation
(data not shown). Mutations in other ER resident enzymes,
such as select protein-disulfide isomerases, also showed no
effect on torsinA or torsinAE (data not shown). Furthermore,
similar to mammalian cells, the defects in N-linked glycosyla-
tion could also be induced by supplementing the growth
medium with DTT (117), but this also occurred in an ire1
yeast mutant in which the unfolded protein response cannot be
induced (data not shown) (118). These results strongly support
our conclusion that compromised torsinA and torsinAE sta-
bility and folding are direct consequences of the lack of Kar2/
BiP, Scj1, and Lhs1 activity.
TorsinAandTorsinAEAreDegraded by the Proteasomeand
Vacuole When Kar2/BiP Function Is Disabled—In mammalian
cells, torsinA and torsinAE are degraded in the lysosome via
autophagy, but torsinAE is also degraded by ERAD (58, 62).
To determine the role of the proteasome and the vacuole (the
lysosome equivalent in yeast) during the turnover of torsinA and
torsinAE when Kar2/BiP function is compromised in yeast, we
deleted PDR5 or PEP4 in the kar2-1 background. The PDR5 dele-
tion allows for efficient MG132-mediated inhibition of protea-
some function (119, 120), and the PEP4 deletion inhibits nearly all
vacuolar protease activity (121). We monitored torsinA and
torsinAE degradation by CHX chase in the kar2-1 pdr5 strain
treated with solvent (DMSO) or MG132 and found that both
torsinAandtorsinAEwerepartiallybut significantly stabilizedby
MG132 (73% versus 58% torsinA and 80% versus 61% torsinAE
remained after 90 min in kar2-1 pdr5 cells treated with MG132
versusDMSO, respectively) (Fig. 6A).
Todeterminewhether vacuolar proteases contribute to torsinA
and torsinAE degradation, we performed a CHX chase in the
kar2-1pep4 strain (Fig. 6B) and found that torsinAwas stabilized
but torsinAE was only partially, yet still significantly stabilized
(91% versus 55% torsinA and 76% versus 59% torsinAE remained
after 90 min in the kar2-1 pep4 and the kar2-1 PEP4 strains,
respectively) (Figs. 3A and6B).Ofnote, torsinAdegradation in the
kar2-1 strain was significantly more dependent on PEP4 than
torsinAE (p 0.04), similar to what has been observed inmam-
malian cells (58, 62). No evidence of torsinA or torsinAE aggre-
gates was observed during chases in the absence of proteasome or
vacuolar function (data not shown).
Defect in Kar2/BiP Function Alters TorsinA and TorsinAE
Membrane Extraction—The Kar2/BiP-dependent defects in
torsinA and torsinAE N-linked glycosylation and the observed
FIGURE 5. The lectin-like chaperones Cne1 and Yos9 do not affect torsinA and torsinAE stability. CHX chases were performed as described before (see
legend for Fig. 3). A, torsinA and torsinAE degradation in CNE1 and cne1 strains. B, torsinA and torsinAE degradation in YOS9 and yos9 strains. Repre-
sentative Western blots are shown below. Experiments were performed at least twice, with2 independent replicates per experiment.
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destabilization of the proteinswhenKar2/BiP functionwas cur-
tailed suggest that this chaperone facilitates the folding of
torsinA and torsinAE.Onemethod tomonitor a change in the
folding of peripheral, membrane-associated proteins is to
determine the relative strength of membrane association. In
other words, defects in folding might lead to greater insolubil-
ity, which would be evidenced by reduced membrane extrac-
tion in the presence of chaotropic agents (29, 101, 102, 122). To
this end, we compared torsinA and torsinAE extraction from
microsomes prepared from wild-type and kar2-1 strains after
treatment with alkaline sodium carbonate buffer (pH 11.5)
(Fig. 7A). As expected, torsinA and torsinAE associated with
the pellet fraction after microsomes prepared from the kar2-1
strain were incubated at pH 6.8 (Fig. 7A, lanes 1, 2, 5, and 6).
Although incubation with sodium carbonate released the
majority of torsinA and torsinAE from the membrane in the
wild-type strain (Figs. 2A and 7C), alkaline extraction was sig-
nificantly less efficient in kar2-1 microsomes (64% versus 25%
torsinA and 88% versus 31% torsinAE remained in the mem-
brane fraction in the kar2-1 and wild-type strains, respectively;
p  0.001) (Fig. 7, A, lanes 3, 4, 7, and 8, and C). Interestingly,
torsinAE associated more avidly with the membrane than
torsinA in the kar2-1 strain (p 0.02), suggesting that the pres-
ence of theEmutation causes a subtle folding defect, which is
exacerbated when Kar2/BiP is disabled.
Kar2/BiP helps maintain substrate solubility, and in its
absence substrates such as pro--factor, CPY*, and CPY oligo-
merize or aggregate (29, 101, 102). To test if decreasedKar2/BiP
function also triggers torsinA and torsinAE aggregation, we
extracted torsinA and torsinAE from membranes collected
from wild-type and kar2-1 cells using the nonionic detergent
Triton X-100. In this experiment, torsinA and torsinAE were
readily extractable by 1% Triton X-100 from microsomes pre-
pared from wild-type cells (Fig. 7B, lanes 1–4). However, in
microsomes prepared from the kar2-1 strain, there was a sig-
nificant increase in the fraction of torsinA and torsinAE that
remained associated with the pellet (51% versus 14% torsinA
and 48% versus 18% torsinAE in the kar2-1 versus the wild-
type strains, p  0.008) (Fig. 7, B, lanes 5–8, and C). All of the
differentially glycosylated species of torsinA and torsinAE in
the kar2-1 strain were extracted to a similar degree both by
detergent and alkali, indicating that the glycosylation state had
no effect on torsinA and torsinAE solubility (Fig. 7). Together,
these results suggest that compromised Kar2/BiP function leads
to folding alterations that decrease torsinAand torsinAE solubil-
ity,which in turn initiates torsinAandtorsinAEaggregation.The
data also provide further support for our hypothesis thatKar2/BiP
is a torsinA chaperone in yeast.
Mutations in TorsinA FunctionalMotifs Exhibit a Synergistic
Interaction with the E Mutation and Destabilize TorsinA—
Mutation of functional domains in torsinA has provided valu-
able information on torsinA function and on the role of the E
allele on disease-associated phenotypes. For example, muta-
tions in torsinA’s C-terminal cysteines prevent a redox-depen-
dent conformational change in torsinA that is critical for
torsinA function (63). TheEmutation yields the same pheno-
type in torsinA as the cysteine mutant, suggesting that it also
impacts local conformation (63). Furthermore, some intragenic
mutations may mimic the effects of cellular or ER stresses in
torsinAE-expressing cells, potentially replicating events that
lead to the manifestation of the DYT1 mutation and EOTD
development. Indeed, mutations in the N-linked glycosylation
sites (Fig. 1A) can alter torsinAE subcellular localization and
inclusion formation in mammalian cells (106). Thus, an exam-
ination of secondarymutations in the context of theE allele in
yeast may unveil previously undiscovered E phenotypes.
FIGURE 6. Loss of Kar2/BiP function causes torsinA and TorsinAE to be degraded by the proteasome and by the vacuole. CHX chases were performed
as described before (see legend for Fig. 3). A, torsinA and torsinAE degradation in the kar2-1 pdr5 strain treated with DMSO or 100 M MG132 for 30 min
before addition of CHX (*, p 0.02 for DMSO torsinA versusMG132 torsinA treatment; p 0.02 for DMSO torsinAE versusMG132 torsinAE treatment). B,
torsinA and torsinAE degradation in the kar2-1 pep4 strain. To facilitate the comparison, we included in the graph the data from the kar2-1 PEP4 strain from
Fig. 3A (*, p 0.002 for kar2-1 PEP4 torsinA versus kar2-1 pep4 torsinA; p 0.02 for kar2-1 PEP4 torsinAE versus kar2-1 pep4 torsinAE). Experiments were
performed at least twice, with2 independent replicates per experiment. Representative Western blots are shown below.
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In our yeast system and in some mammalian cell studies, no
difference was observed in the stability of torsinA and torsinAE
(Figs. 3–5) (63). However, torsinAE showed enhanced mem-
brane association compared with torsinA in the kar2-1 strain
(see above, Fig. 7). The data suggest that the lack of key chap-
erones can exacerbate subtle effects of the E allele, which
appear otherwise indistinguishable from the wild-type allele by
our methods. We reasoned that torsinAE instability may also
be magnified if the E allele is combined with additional intra-
genic mutations. Therefore, we set out to explore the effects on
torsinA and torsinAE stability when other mutations were
engineered into distinct functional domains in torsinA.
TorsinA has two asparagines to which N-linked glycans are
added (Asn-143 and Asn-158; Fig. 1A) (106, 123). To examine
how the presence of theEmutation affects torsinA stability in
combination with mutations in the first (N143Q) or second
(N158Q) N-linked glycosylation sites, we performed CHX
chases in a wild-type strain (KAR2) transformed with the tor-
sinA and torsinAE alleles carrying either of these secondary
mutations (Fig. 8A). The N143Q mutation had no significant
effect on the stability of torsinA or torsinAE (89% torsinA-
N143Q versus 81% torsinA and 84% torsinAE-N143Q versus
84% torsinAE remained after 90 min) (Fig. 9B). The N158Q
mutation also had no significant effect on torsinA stability (74%
of torsinA-N158Q versus 81% torsinA remained after 90 min)
(Figs. 8A and 9B). However, the N158Q mutation significantly
decreased torsinAE levels (42% torsinAE-N158Q versus 84%
torsinAE remained after 90 min, p 0.0004) (Figs. 8A and 9B).
These results are in accordance with data suggesting a more
prominent role of glycosylation at position Asn-158 in
torsinAE inmammalian cells (106) and indicate that glycosyl-
ation at position Asn-158 is critical to stabilize torsinAE but
not torsinA.
The integrity of the Walker motifs is essential for the func-
tion of AAAATPases (48, 124–126). Indeed,mutations in the
Walker motifs that are predicted to disrupt ATP binding
(K108A) or hydrolysis (E171Q) (Fig. 1A) (48, 63, 124, 125, 127)
can alter torsinA and/or torsinAE subcellular localization,
inclusion formation, and/or binding to interacting partners in
mammalian cells (56, 60, 61, 63, 127–129). To test how the E
mutation affects torsinA stability in the presence of mutations
in theWalker motifs, we performed CHX chase experiments in
a wild-type strain (KAR2) transformed with torsinA and
torsinAE alleles carrying either of these additional mutations
(Fig. 8C). The K108A mutation led to a significant decrease in
the stability of both torsinA and torsinAE (40% torsinA-
K108A versus 81% torsinA and 20% torsinAE-K108A versus
84% torsinAE remained after 90 min, p  0.0007) (Figs. 8C
FIGURE 7. Kar2/BiP maintains torsinA and torsinAE membrane association and solubility. Microsomes prepared from log phase wild-type (KAR2) or
kar2-1 yeast cells grown at 28 °C and that express torsinA (T) or torsinAE (E) were incubated for 30 min in ice in pH 6.8 buffer or pH11.5 carbonate buffer
(A) or in apH6.8buffer containing1%TritonX-100 (B). After centrifugationat 100,000g, aliquotsofproteins fromthe supernatant (S) or thepellet (P) fractions
were separated by SDS-PAGE, and the presence of torsinA and torsinAE was detected by Western blot analysis and quantified. Significant p values for the
carbonate extraction are as follows: *, p 0.001 for KAR2 torsinA versus kar2-1 torsinA; p 0.001 for KAR2 torsinAE versus kar2-1 torsinAE; ¥, p 0.02 for
kar2-1 torsinA versus kar2-1 torsinAE; and for Triton extraction are as follows: *, p 0.008 KAR2 torsinA versus kar2-1 torsinA; p 0.002 for KAR2 torsinAE
versus kar2-1 torsinAE. C, graph shows the means  S.E. of the fraction of torsinA or torsinAE remaining in the pellet from at least three independent
experiments.
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and 9B). On the contrary, although the E171Q mutation
appeared to increase the stability of torsinA (94% torsinA-
E171Q versus 81% torsinA remained after 90 min), it signifi-
cantly destabilized torsinAE (55% torsinAE-E171Q versus
84% torsinAE remained after 90 min, p  0.0007) (Figs. 8C
and 9B). Therefore, mutations in the Walker-B motif led to
opposite effects on torsinA stability, depending on the presence
of the E mutation. Importantly, both the K108A and E171Q
mutations had a greater destabilizing effect on torsinAE than
on torsinA (p  0.03) (Fig. 9B). K108A-mediated destabiliza-
tion in torsinA and torsinAE and the stabilizing effect of the
E171Qmutation in torsinAare inagreementwith results forother
AAA ATPases (124, 126, 130). Overall, these experiments sup-
port our hypothesis that theEmutation harbors a subtle folding
defect and that this defect is amplified in thepresenceof additional
mutations that affect torsinA conformation.
A naturally occurring polymorphism inE carriers (Asp-216
to His-216) influences E penetrance (Fig. 1A) (131, 132). The
D216H mutation alters torsinAE inclusion formation in
mammalian cells and counteracts torsinAE-associated ER
stress in a Caenorhabditis elegansmodel (93, 94). To test if the
D216H mutation influences torsinA and torsinAE stability,
we performed CHX chases (Fig. 9A). We found that introduc-
tion of the D216Hmutation did not change the stability or glyco-
sylation status of torsinA or torsinAE in a wild-type strain (85%
torsinA-D216H versus 81% torsinA and 78% torsinAE-D216H
versus 84% torsinAE remained after 90 min) (Fig. 9).
Decreased Kar2/BiP function significantly destabilized both
torsinA-D216H and torsinAE-D216H (p 0.02) but at simi-
lar levels as torsinA and torsinAE (66% torsinA-D216H versus
55% torsinA, and 60% torsinAE-D216H versus 59% torsinAE
remained after 90 min in the kar2-1 strain) (Fig. 9). We
observed that torsinA-D216H appeared somewhat more stable
than torsinAE-D216H in the wild-type strain (Fig. 9), but this
difference was not significant (p
 0.084). These results suggest
that the synthetic effects of the D216H mutation observed in
patients andC. elegansmodels are not caused by altered torsinA
stability.
FIGURE 8. Synergismbetweenmutations in functionalmotifs and theEmutation anddual role of Kar2/BiP in torsinAand torsinAEdegradation.A,
defect in N-linked glycosylation triggers the Kar2/BiP-dependent degradation of torsinAE. CHX chases were performed as described before (see legend for
Fig. 3).KAR2 (A andC) and kar2-1 (B andD) strains expressing torsinAor torsinAE containing (A andB) Asn-Glnmutations that prevent glycosylation atAsn-143
(N143Q) andAsn-158 (N158Q). (*, p 0.0004 for torsinAE versus torsinAE-N158Q in the KAR2 strain); ormutations in theWalker-Amotif (K108A) orWalker-B
motif (E171Q) (C andD). (*, p 0.0007 for torsinA versus torsinA-K108A in the KAR2 strain; p 0.00001 for torsinAE versus torsinAE-K108A in the KAR2 strain;
p 0.003 for torsinAE versus torsinAE-E171Q in the KAR2 strain). Below are representative Western blots used for quantitation. Experiments were done at
least twice with2 independent replicates/experiment.
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Kar2/BiP Plays a Dual Role during TorsinA and TorsinAE
Biogenesis—Loss of Kar2/BiP led to the formation of incom-
pletely glycosylated forms of torsinA and torsinAE and to a
decrease in protein stability (Fig. 3). In our assays, all the differ-
entially glycosylated species in the kar2-1 strain behaved simi-
larly (Figs. 3 and 7). However, our results also indicate that
robust glycosylation is required for torsinAE stability in a
wild-type strain (Fig. 8A). These observations can be reconciled
by previous results in yeast that demonstrate that chaperone
requirements can vary depending on a protein’s glycosylation
state (133, 134). Thus, we hypothesized that although Kar2/BiP
is required for stabilizing fully glycosylated torsinA and
torsinAE (Fig. 3A), it is also required to degrade the mono-
and unglycosylated torsinAE species. To test this model, we
performed CHX chases of torsinA and torsinAE containing
the N143Q or N158Q mutations in the kar2-1 strain (Figs. 8B
and 9B). In agreement with our model, the lack of Kar2/BiP
function significantly stabilized torsinAE-N158Q (69%
torsinAE-N158Q versus 42% remained after 90 min in the
kar2-1or thewild-type strains, respectively,p 0.002) (Figs. 8B
and 9). We also found that torsinA-N143Q was significantly
destabilized in the kar2-1 strain (75% versus 89% torsinA-
N143Q remained after 90 min in the kar2-1 and the wild-type
strains, respectively, p  0.03) (Figs. 8B and 9B). This result
suggests that a lack ofN-linked glycans at N143 in torsinA does
not impact the role ofKar2/BiP inmaintaining torsinA stability.
On the contrary, although there was a clear trend toward lower
stability in the kar2-1 strain, neither torsinA-N158Q nor
torsinAE-N143Q stability was significantly altered in the
kar2-1 strain (65% versus 74% torsinA-N158Q and 76% versus
85% torsinAE-N143Q remained after 90 min in the kar2-1 or
the wild-type strains, respectively). This result suggests that
either lack of N-linked glycans at Asn-158 in torsinA and at
Asn-143 in torsinAE abrogates Kar2/BiP dependence for sta-
bility or that these species are protected from degradation in
the absence of Kar2/BiP (Figs. 8 and 9). Thus, combined with
the data provided above (Figs. 3 and 8, A and C), Kar2/BiP can
play either a pro-degradative or a pro-folding role depending on
the glycosylation state of torsinA and torsinAE.
To determine whether Kar2/BiP’s dual role was only associ-
ated with torsinA’s glycosylation state or was more generally
associated with protein folding, we measured the stability of
torsinA and torsinAEWalker-A andWalker-Bmutants in the
kar2-1 strain (Fig. 8D). Consistent with the acquisition of an
altered conformation, the degradation of torsinA-K108A,
torsinAE-K108A, and torsinAE-E171Q was significantly
attenuated in the kar2-1 strain (57% versus 40% torsinA-
K108A, 66% versus 20% torsinAE-K108A, and 72% versus 55%
torsinAE-E171Q remained after 90 min in the kar2-1 and
wild-type strains, respectively, p 0.04) (Figs. 8D and 9B). On
the contrary, torsinA-E171Q was significantly destabilized in
kar2-1 yeast compared with the wild-type strain (59% versus
94% torsinA-E171Q remained after 90 min in the kar2-1 and
wild-type strains, respectively, p  0.01) (Figs. 8D and 9B).
Taken together, these results indicate that Kar2/BiP plays a
dual role during torsinA degradation, which is linked to the
folding or conformational states of torsinA.
FIGURE 9. The D216Hmutation does not significantly affect torsinA or torsinAE stability. CHX chases were performed as described before (see legend
for Fig. 3). A, torsinA-D216H and torsinAE-D216H degradation in KAR2 and kar2-1 strains. Representative Western blots are shown below. Experiments were
performed at least three times, with2 independent replicates per experiment. (*, p 0.001 for torsinA-D216H in the KAR2 versus kar2-1 strains; p 0.02 for
torsinAE-D216H in the KAR2 versus kar2-1 strains.) B, comparative graph showing the effects of themutations in Figs. 8 and 9 on torsinA and torsinAE levels
at the 90 min time point of the CHX chases in the KAR2 and kar2-1 strains. Specific mutations in the N-glycosylation, Walker-A and B motifs, or D216H are
indicated. *, other relevant p values not already described in Figs. 3 and 8 (p  0.03 for torsinA-N143Q in the KAR2 versus kar2-1 strains; p  0.003 for
torsinAE-N158Q in the KAR2 versus the kar2-1 strains); p 0.04 for torsinA-K108A in the KAR2 versus kar2-1 strains; p 0.01 for torsinA-E171Q in the KAR2
versus kar2-1 strains; p 0.0002 for torsinAE-K108A in the KAR2 versus kar2-1 strains; p 0.03 for torsinAE-E171Q in the KAR2 versus kar2-1 strains.
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BiPAlso Promotes TorsinAandTorsinAEStability inMam-
malian Cells—To test whether the mammalian BiP homolog
also contributes to torsinA and torsinAE biogenesis in mam-
malian cells, we first compared the levels of torsinA and
torsinAE in HeLa cells in which BiP expression was silenced
using siRNA (Fig. 10A). We designed a protocol using the BiP-
specific siRNA 077 to obtain a reduction of BiP levels by55%
compared with a control siRNA, to prevent defects in cellular
viability caused by greater BiP silencing (data not shown).
These data are consistent with previous observations that BiP
levels cannot be reduced to 40% of wild-type levels (2). Also
consistent with previous data (135, 136), the depletion of BiP
was accompanied by the induction of Grp94, which is another
major ER chaperone (Fig. 10A). Under these conditions, the
steady state levels of both torsinA and torsinAE were
decreased by 70–75% compared with the negative control (Fig.
10). Similar results were observed using another BiP-targeted
siRNA (data not shown). These results suggest that BiP affects
the stability of both torsinA and torsinAE inmammalian cells.
To confirm these data, we implemented a second approach
to deplete BiP. To this end, we performed a torsinA pulse-chase
in HeLa cells transiently expressing torsinA or torsinAE in
which BiP levels were acutely reduced by means of the AB5
subtilase cytotoxin, also known as the SubAB toxin (Fig. 11).
SubAB is a bacterial serine protease that cleaves and inactivates
BiP rapidly and specifically (87). Indeed, only 45 min after the
toxin was added to the culture medium (t 
 “0” min of the
chase), BiP levels dropped to 35% of the levels of BiP in cells
treated with the catalytically inactive toxin, SubAA272B (Fig.
11A). Moreover, BiP could not be detected by Western blot in
toxin-treated cells 1 h into the chase, whereas the catalytically
inactive toxin had no effect on BiP (Fig. 11A). As anticipated,
the reduction of BiP upon SubAB treatment also significantly
destabilized torsinA (26% versus 44% of torsinA remained after
a 4-h chase in cells treated with SubAB or SubAA272B, respec-
tively, p 0.02) (Fig. 11,A andB). Similar results were observed
if only the fully glycosylated bands were quantified (data not
shown). Although the effect was less pronounced, there was
also a difference in torsinAE stability in the presence of active
or inactive toxin (31% versus 39% torsinAE remained after a
4-h chase in cells treated with SubAB or SubAA272B, respec-
tively) (Fig. 11, A and B). We also noticed that the levels of un-
glycosylated torsinA and torsinAEwere higher at the beginning
of the chase after toxin treatment compared with inactive toxin
treatment or no treatment (72% versus 53% of unglycosylated
torsinA and torsinAE in SubAB versus SubAA272B-treated
cells or -untreated cells, respectively) (Fig. 11,A andC, data not
shown and (63)). Because the unglycosylated species appears to
mature into the fully glycosylated form of torsinA, the more
rapid disappearance of torsinA is likely not due to the selective
turnover of the unglycosylated protein (Fig. 11A). In fact, the
unglycosylated form degraded similarly irrespective of whether
the sample was treated with SubAB or SubAA272B (data not
shown). Furthermore, because of the acute nature of the subti-
lase treatment, the effect on torsinAmaturation and stability is
unlikely to be caused by the up-regulation of other chaperones.
In contrast to the knockdown experiments, GRP94 levels did
not vary during the4-h treatment with the toxin (Fig. 10 and
data not shown). Taken together, the results using toxin-medi-
ated BiP depletion are in accordance with the results using
RNAi-mediated depletion of BiP in mammalian cells and with
the experiments in the yeast genetic system, and establishBiP as
a torsinA chaperone.
DISCUSSION
EOTD, one of the most common forms of inherited primary
dystonias, is associated with a dominant E302/303 mutation
in the gene DYT1, which encodes the ER/nuclear envelope
localizedAAAATPase torsinA (43, 44). However, the variable
phenotypic manifestation and low penetrance of the E muta-
FIGURE 10. siRNA-mediated knockdown of BiP reduces the steady state
levels of torsinA and torsinAE.HeLa cells were treatedwith siRNA against
BiP for a total of 48 h andwere transfectedwith torsinA (T) and torsinAE (E)
expression vectors 24 h before harvest. A, representative Western blot; B,
graph showing the average S.E. of the normalized levels of BiP, torsinA, and
torsinAE after treatment with a control siRNA or siRNA directed against BiP
(077). Experiments were performed at least twice with three replicates per
experiment. Thegraphedvalueswerenormalized as follows. The levels of BiP,
torsinA, and torsinAE for each replicate ineachexperimentwerenormalized
first to the corresponding actin levels. Then the actin-normalized value from
one siRNA control replicate was used to normalize the values of all other
replicates. This procedure was performed for each torsinA and torsinAE
experiment independently. Actin was used as loading control. Grp94 levels
were also monitored by Western blot.
FIGURE 11.BiP is required for torsinA and torsinAE stability inmamma-
lian cells.HeLa cells transiently transfectedwith torsinA-HA or torsinAE-HA
expression vectors were treated with 0.5 g/ml of an active SubAB or a cata-
lytically inactive SubAA272B toxin for 45 min before a pulse-chase was per-
formed (t
 0).A, BiP and torsinA levelsweremonitored at each time point by
Western blot (WB) and autoradiography, respectively. B, graph showing the
average S.E. of total torsinA or torsinAE remaining at the 4-h time point in
the presence of SubAB or SubAA272B toxin quantified relative to that at the
0-h time point. (*, p  0.02 for torsinA in cells treated with SubAB versus
SubAA272B). C, graph showing the average  S.E. of the relative levels of
unglycosylated/total torsinA or torsinAE at the 0-h time point in the pres-
ence of SubAB or SubAA272B toxin (*, p  0.002). Experiments were per-
formed at least three times with at least one replicate/experiment.
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tion (45) indicate that additional environmental or genetic fac-
tors must play a role in EOTD onset. One hypothesis is that E
impacts torsinA folding, and thus modifies torsinA’s half-life,
solubility, and/or interaction with chaperones, as evident in
other genetic “conformational” diseases (34). Cellular chaper-
one levels are sensitive to genetic and environmental insults.
Thus, altering chaperone levels could augment the phenotypes
associated with the E mutation. By understanding the chap-
eronemicroenvironment required for the folding, stabilization,
and degradation of wild-type torsinA and of the disease-associ-
ated torsinAE variant, we hope to identify cellular factors that
can be targeted with therapeutics. In this work, we report for
the first time on ER chaperones required for torsinA and
torsinAE biogenesis.
We discovered that Kar2/BiP is required to maintain the
N-glycosylation and solubility of torsinA and torsinAE in a
yeast model (Figs. 3 and 7) and that in the absence of Kar2/BiP,
torsinA and torsinAE are destabilized and degraded (Figs. 3
and 6). In addition, we obtained preliminary evidence that the
proteins are ubiquitinated (data not shown), which is in agree-
ment with a recent study showing that the E3 ubiquitin ligase,
FBG1, is involved in the degradation of torsinA and torsinAE
(137).We also found that Kar2/BiP plays a pro-degradative role
when the stability of torsinA and torsinAE is compromised
(Figs. 8 and 9). Finally, we provide evidence that BiP supports
torsinA biogenesis in human cells (Figs. 10 and 11). Therefore,
to our knowledge, BiP is the first ER molecular chaperone that
has been reported to facilitate the maturation of torsinA and
torsinAE.
The E mutation affects torsinA’s redox-sensitive confor-
mational changes, potentially by altering the local structure of
an -helix in the C-terminal subdomain (63, 94). Nevertheless,
several studies have failed to uncover significant structural dif-
ferences between torsinA and torsinAE, suggesting that the
E mutation confers a more subtle effect on torsinA’s struc-
ture (91, 94). This idea is supported by our observations that the
E mutation increases torsinA membrane association in the
absence of functional Kar2/BiP (Fig. 7) and that the E muta-
tion andmutations in several functional motifs exhibit a syner-
gistic interaction that alters torsinA stability (Figs. 8 and 9).
These data also suggest that the effect of theEmutation could
be amplified through secondary genetic or environmental
insults, potentially mimicking the sequence of events that is
required to manifest the dominant but poorly penetrant E
mutation (45, 91, 94). Indeed, the secondary mutations we
incorporated might mimic alterations in the availability or
function of chaperones, enzymes, or interacting partners,
which in turn could play a role in EOTD onset and/or
progression.
N-Linked glycosylation is a post-translational modification
that is intimately involved in ER protein quality control (4, 138).
Defects in N-glycosylation are associated with several human
diseases (139–141). Interestingly, we found that defects in
Kar2/BiP or its associated Hsp40s (Scj1 and Jem1) altered
torsinA and torsinAE N-glycosylation, but this defect was
uncoupled from destabilization (Figs. 3 and 4). How do these
chaperones impact N-linked glycosylation? The kar2-1 (BiP
mutant) allele has not been shown to affect the glycosylation of
other secreted substrates; therefore, a general effect on the
glycosylation machinery can be ruled out. The efficiency of
N-linked glycosylation is not only determined by the amino
acid sequence to which the modification is appended (the
NX(S/T) tripeptide motif) but is also affected by secondary and
tertiary structure, hydrophobic collapse, and disulfide bond
formation (142). Notably, torsinA has two asparagines that can
be glycosylated, Asn-143 and Asn-158 (Figs. 1 and 3) (65, 123).
It is possible that the presence of the cysteine at position 162
(Fig. 1A) may affect glycosylation at the second acceptor site,
N158VS, by altering the local conformation through the forma-
tion of an intramolecular disulfide bond (143) or by forming a
covalent bond with the oligosaccharyltransferase during trans-
location (144). Any effect on glycosylationmay be potentiated if
the polypeptide is improperly folded due to compromised
chaperone function, e.g. when torsinA is expressed in the
kar2-1 yeast. This hypothesis is supported by the observations
that treatment with the reducing agent, DTT, or deletion of the
N-terminal hydrophobic domain in torsinA (Fig. 1A) leads to a
similar glycosylation defect observed in the kar2-1 strain.5 Fur-
thermore, torsinA interacts with the chaperone and lectin cal-
nexin inmammalian cells (60). S. cerevisiae lacks a true calnexin
(145). Calnexin and calreticulin have been shown to compete
with BiP for binding to specific glycoproteins (112), but cal-
nexin also binds nonglycosylated substrates (146). This may
explain why compromised Kar2/BiP function in yeast leads to a
co-translational folding defect (evidenced by the appearance of
different glycosylated species) that is not observed in mamma-
lian cells (Figs. 3 and 9). Overall, our results indicate that
torsinA and torsinAE glycosylation is sensitive to alterations
in folding caused not only by the absence of specific chaperones
but also by environmental insults and by intragenic mutations.
Protein aggregation can lead to profound effects on cell via-
bility (147). A critical role played by molecular chaperones,
including Kar2/BiP, is to maintain the solubility of nascent
polypeptides until their final conformations are achieved (29,
148). Themembrane extraction of torsinA and torsinAE with
carbonate or a nonionic detergent was severely impaired in the
absence of Kar2/BiP (Fig. 7). In principle, this phenotype could
be due to a translocation defect, but translocation of the pro-
teins into the ER was unaffected in the kar2-1 strain (Fig. 3C).
More likely, enhanced membrane association arose from con-
formational changes that expose hydrophobic regions, which
would enhance membrane association or which could lead to
aggregation (122). Alternatively, torsinA and torsinAE might
associate with other proteins that aggregate in the kar2-1 strain
(29). This model would be consistent with the proposed chap-
erone function of torsinA (53–55, 149), although no effect of
torsinA or torsinAE on the ERAD of select substrates was
observed in yeast (data not shown), and only terminally mis-
folded ERAD substrates have been reported to aggregate in the
kar2-1 yeast (29).
The introduction of mutations in torsinA and torsinAE
generally led to a more profound loss of stability in torsinAE
than in torsinA (Figs. 8 and 9). Lack ofN-linked glycosylation at
5 L. F. Zacchi and J. L. Brodsky, manuscript in preparation.
BiP Chaperones TorsinAMaturation
12742 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 18•MAY 2, 2014
 at UQ Library - St.Lucia on July 27, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Asn-158 specifically affects torsinAE, both in mammalian
cells and in our yeast model (Fig. 8) (106). Defects in glycosyla-
tion can impact local folding, alter the interaction with lectins
and chaperones, and reduce protein solubility (138). Thus, it is
possible that the glycan at Asn-158 is required for the interac-
tion of torsinA and torsinAE with chaperones or lectins,
which torsinAE may require for folding. This effect, in turn,
would lead to increased degradation of torsinAE but not
torsinA. Alternatively, altered folding caused by the lack of a
glycan at Asn-158 may impact the ability of torsinAE to form
hexamers, which is the typical oligomeric state assumed by
AAA ATPases, including torsinA (48, 61, 150). These unas-
sembled torsinAEmonomersmay be targeted for degradation
via the ERAD pathway (10, 151). This model may also explain
why mutating the Walker-A motif triggers torsinA and
torsinAE degradation, whereas mutating the Walker-B motif
stabilizes torsinA (Figs. 8 and 9). The K108A mutation in the
Walker-A motif of AAA ATPases not only prevents ATP
binding, it also impairs substrate interaction and hexamer for-
mation (48, 152). Conversely, the E171Q mutation in the
Walker-B motif locks the protein in an ATP- and substrate-
bound conformation and promotes hexamer stabilization (48,
152). In the case of torsinAE, the C-terminal conformational
defect and the lack of binding to interacting partners required
for ATPase activity (63, 127)may prevent efficient hexameriza-
tion, a phenotype that could be aggravated by the E171Qmuta-
tion. This phenomenon would explain why the E171Q muta-
tion destabilizes torsinAE (Fig. 9B).
Besides protecting nascent polypeptides and aiding in their
folding, chaperones can also identify and target terminally mis-
folded intermediates for degradation (4, 9). Thus, depending on
the substrate, chaperones can have a pro-folding and/or a pro-
degradative role (109). For example, mammalian Hsp/c70 is a
key pro-folding factor for CFTR that can also act as a pro-deg-
radative chaperone, targeting CFTR for ERAD (153). The loss
of stability of torsinA and torsinAE containing additional
mutations in functional motifs also uncovered a dual role of
Kar2/BiP on the folding and stabilization of these proteins
(Figs. 8 and 9). Kar2/BiP normally aids in folding torsinA and
torsinAE (Figs. 3 and 8–11) but is instead a pro-degradative
factor when the stability and folding of torsinA and torsinAE
are impaired by mutations in specific functional motifs (Figs. 8
and 9). This dual role of Kar2/BiP is not unprecedented. Kar2/
BiP functions as a pro-folding chaperone for the vacuolar pro-
tease CPY but as a pro-degradative factor of the ERAD sub-
strate CPY* (100, 102). Moreover, BiP aids in the folding and
assembly of monomers into oligomers, while simultaneously
contributing to the degradation of the unassembled, potentially
misfolded monomeric subunits (154–157). Thus, Kar2/BiP
may help torsinA and torsinAE to fold (Fig. 3) and hexamer-
ize, while also facilitating the degradation of the torsinA and
torsinAE monomers that fail to assemble into hexamers due
to, for instance, the presence of the additional mutations men-
tioned above (Figs. 8 and 9). Alternatively, Kar2/BiPmay simply
recognize misfolded features of the mutated torsinA and
torsinAE and aid in their degradation. These results illustrate
the complex relationship between chaperones and their sub-
strate clients, and underscore the delicate equilibrium between
folding and degradation that ultimately dictates the fate of fold-
ing intermediates.
Because BiP is associatedwith the development of diseases as
diverse as cancer and Parkinson disease (20, 31–33, 158, 159),
there is growing interest in developing small molecule modula-
tors of BiP. Chemical modulators of BiP activity have been
developed and tested in vitro (87, 160), and smallmolecules that
enhance the activity of cytosolic Hsp70 exist (161), which may
be adapted in the future to act on BiP. Alternatively, the expres-
sion levels of BiP can be modified, a procedure that has shown
therapeutic potential both in vitro and in mouse models (162–
166). Because our results demonstrate that BiP stabilizes
torsinA and torsinAE, and because patients afflicted with
EOTD are heterozygous for the E mutation, the design of
effective therapies may need to combine the modulation of BiP
activity/expression levelswith themodulation of secondary tar-
gets that selectively affect torsinAE folding such as the glyco-
sylation machinery (Fig. 8). A deeper understanding of the
molecular and environmental factors that alter the biochemical
properties of torsinA and of the factors that participate in
torsinA folding and degradation will provide new clues to
define the etiology of EOTD and may identify new therapeutic
targets to prevent or treat the disease.
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